FierceBiotech chats with a pair of lawyers about how drug pricing is unique in the U.S. and how the biopharma environment lends itself to selling hype and securities fraud.

The FierceMadness drug name showdown and how do drugs get their zany names anyway?

Mar 13th, 2018 21m 26s

Fierce editors discuss the 2018 FierceMadness drug name tournament, its origins, and our favorites heading into the competition, while Scott Piergrossi, vice president of creative development at the Brand Institute, talks us through the history

Back from the dead: FierceBiotech Radio at the Battle of the Biotech Bands

Oct 31st, 2017 9m 46s

FierceBiotech Radio rose from the grave for this special Halloween episode where we sat down with some of the scientists, account associates and operations managers who competed in 2017's Battle of the Biotech Bands.

GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster

Mar 18th, 2016 28m 41s

Fierce editors discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decision with a big Alzheimer's trial and Valeant Pharmaceuticals' rough week.

The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'

Feb 26th, 2016 41m 26s

Fierce editors discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts to undercut Novo Nordisk in diabetes, and a novel approach to regulating drug costs.

Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals

Feb 18th, 2016 39m 23s

Fierce editors discuss the rise of TV ads for specialty drugs, signs of life in the biotech IPO scene, and the case for Intercept Pharmaceuticals as a buyout target.

Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars

Feb 11th, 2016 40m 30s

Fierce editors discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world of biosimilars.

Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover

Feb 4th, 2016 36m 41s

Fierce editors discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to right the ship.

Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup

Jan 8th, 2016 22m 37s

Fierce editors discuss Shire's increasingly complicated ambition to acquire Baxalta, the changing climate of biotech venture capital and the future of Valeant Pharmaceuticals.

The burning hole in Gilead's $25B pocket and AbbVie's future in hematology

Dec 10th, 2015 19m 52s

Fierce editors discuss the discussion around Gilead Sciences' huge cash reserve and the many things the company might buy. Plus, a look back at AbbVie's blockbuster buyout of Pharmacyclics and a thoughtful consideration of how a certain biotech

Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place

Dec 3rd, 2015 24m 31s

In an episode free of Valeant Pharmaceuticals and Martin Shkreli, Fierce editors discuss a Senate investigation into Gilead Sciences' pricing of the hepatitis C drug Sovaldi, BioMarin's efforts to win approval for a rare disease treatment and G

The ins and outs of 'Pfizergan,' whatever it is Martin Shkreli's doing and the end of two takeover battles

Nov 24th, 2015 28m 35s

Fierce editors discuss the long-awaited merger agreement between Pfizer and Allergan, Martin Shkreli's CEO double duty, and the whimpering conclusion of two hostile takeovers.

Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit

Nov 12th, 2015 32m 2s

Fierce editors discuss Sanofi's uninspiring forecast, Amgen's return to high-dollar dealmaking and a lawsuit that accuses a drug company of deliberately being bad at making drugs.

Fraud's not that big of a deal: the Valeant story, according to Bill Ackman

Nov 5th, 2015 29m 46s

Fierce editors discuss the latest turns in the Valeant Pharmaceuticals saga, the seeming inevitability of a Pfizer-Allergan merger, and Shire's up-and-down efforts to buy stuff it wants.

Valeant's semantic innovation, Pfizer's future and the slow trickle of biotech IPOs

Oct 29th, 2015 25m 8s

Fierce editors discuss a fascinating Valeant Pharmaceuticals conference call, Pfizer's desire for a big buyout and the creaky world of biotech IPOs.

Doomsdays for Valeant, Biogen and biotech VC

Oct 22nd, 2015 21m 50s

Fierce editors discuss a rough day for Valeant Pharmaceuticals and Biogen, plus the changing in winds in biotech venture capital.

Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand

Oct 15th, 2015 28m 55s

Fierce editors discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, and Merck KGaA's big push to distance itself from that other Merck.

Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot

Oct 8th, 2015 26m 30s

Fierce editors discuss another rough week for biotech stocks, Valeant Pharmaceuticals' doggedness in the face of congressional inquiry, and a curious new trend in pharma advertising.

Valeant feels the Bern, biotech buckles on Wall Street, and Bristol-Myers turns to Family Feud

Oct 1st, 2015 21m 43s

Fierce editors discuss how concerns about drug pricing have affected biopharma companies large and small, the latest threat to the biotech bubble, and Bristol-Myers Squibb's interesting televisual choices.

John Carroll on Turing Pharma and Martin Shkreli

Sep 22nd, 2015 14m 58s

FierceBiotech's John Carroll discusses his personal experience with the ongoing fallout over Turing Pharmaceuticals' drug pricing and CEO Martin Shkreli's public response.

Lilly and Boehringer's 'amazing' diabetes data, biotech's VC boom, and Severin Schwan's hot mic

Sep 18th, 2015 28m 23s

Fierce editors discuss some surprising trial results for a diabetes drug from Eli Lilly and Boehringer Ingelheim, the continued flow of money into private biotech companies, and the public frankness of Roche CEO Severin Schwan.

GlaxoSmithKline's horrible, no good, very bad year; Kyle Bass' 'truthful irrelevancy'; and the return of vanity pharma websites

Sep 11th, 2015 26m 36s

Fierce editors discuss the latest setback in a bad run of form for GlaxoSmithKline, Kyle Bass' trouble with drug patents, and a new twist in the buyout battle between Horizon Pharma and Depomed.

Valeant's fantasy football M&A, the gathering PCSK9 storm, and Novartis' alarming new campaign

Sep 4th, 2015 28m 13s

Fierce editors Carly Helfand and Damian Garde discuss Valeant Pharmaceuticals' latest reclamation projects, the bad-cholesterol horse race between Sanofi and Amgen, and Novartis' apparent horror-movie aspirations. Peace to Wes Craven.

The future of 'female Viagra,' the return of Allergan buyout chatter, and an overuse of the word 'allegedly'

Aug 20th, 2015 28m 55s

Fierce editors discuss the controversial FDA approval of the first libido drug for women, what Allergan should buy next, and Retrophin's lawsuit against former CEO Martin Shkreli.

Amarin's First Amendment crusade, Martin Shkreli's Twitter and Kim Kardashian's Instagram

Aug 13th, 2015 31m 55s

Fierce editors discuss a court ruling that could change how pharma companies market drugs, a biotech CEO's nuanced relationship with Twitter, and how Kim Kardashian's Instagram drew the ire of the FDA.